Rule 8 - (Cambridge Antibody)
March 27 2003 - 5:42AM
UK Regulatory
RNS Number:2826J
JP Morgan Investment Management Inc
27 March 2003
FORM 8.1/8.3
Lodge with Company Announcements Office (which will publicise and copy
to the Panel).
Use separate form for each class of securities in which dealings have
been made.
Date of disclosure 27th March 2003
DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) AND 8.3
OF THE CITY CODE ON TAKE-OVERS AND MERGERS
Date of dealing 26th March 2003
Dealing in Cambridge Antibody Technology Group plc (name of company)
(1) Class of securities (eg ordinary shares) Ordianry Shares
(2) Amount bought
Amount Sold
26,734
Price per unit
380 p
(3) Resultant total of the same class owned or controlled
(and percentage of class) 346,873 ( 0.95 %)
(4) Party making disclosure J.P. Morgan Investment Management Inc
(5) EITHER (a) Name of purchaser/vendor (Note 1)
OR (b) If dealing for discretionary client(s), name of fund management
organisation
J.P. Morgan Investment Management Inc
(6) Reason for disclosure (Note 2)
(a) associate of (i) offeror (Note 3) NO
(ii) offeree company NO
Specify which category or categories of associate (1-8)
If category (8), explain
(b) Rule 8.3 (ie disclosure because of ownership or control of 1% or more
of
the class of relevant securities dealt in) YES
Signed, for and on behalf of the party named in (4) above
(Also print name of signatory) Mukesh Halai
Telephone and extension number 020 7325 9925
This information is provided by RNS
The company news service from the London Stock Exchange
END
DCCEAFDXALFDEFE